BofA raised the firm’s price target on Viatris to $10 from $9 and keeps an Underperform rating on the shares, citing a sector re-rating. The firm, which forecasts Q4 sales and EBITDA roughly in-line with consensus, says its multiple for Viatris reflects a lack of growth and track record of accretive business development.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VTRS: